Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GLUCHIRAL

Financiado

Molecular chirality tools for the study of Gluten Immunogenic Peptides and Celia...

Molecular chirality tools for the study of Gluten Immunogenic Peptides and Celiac Disease: Novel therapeutic and diagnostic approaches. Celiac disease (CD) is a systemic autoimmune disorder triggered by gluten consumption in genetically predisposed individuals, affecting a substantial portion of the European population (1.4%). A significant number of CD cases rema... ver más

29/02/2028

226K€

Presupuesto del proyecto: 226K€

Líder del proyecto

UNIVERSIDAD DE SEVILLA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 3670

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-15

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

226.44K€ | Lider

BIOMEDAL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2015-4402-1 Investigación de un microorganismo con capacidad para degrad... 351K€ Cerrado

SAF2015-64306-R CARACTERIZACION DE LA ACTIVIDAD GLUTENASICA HUMANA: UNA FUEN... 157K€ Cerrado

SAF2017-83700-R METABOLOMICA DEL GLUTEN: CARACTERIZACION Y ESTUDIO DE PATRON... 145K€ Cerrado

PDC2022-133344-I00 VALIDACION Y DESARROLLO DE UNA GLUTENASA PARA EL TRATAMIENTO... 133K€ Cerrado

SOMIT-CD Novel First-in-Class Specific Oromucosal Immunotherapy (SOMI... 4M€ Cerrado

PID2020-119044GB-I00 CARACTERIZACION DE LA FIRMA MICROBIANA ASOCIADA A LA ENFERME... 169K€ Cerrado

Duración del proyecto: 46 meses Fecha Inicio: 2024-04-15
Fecha Fin: 2028-02-29

Líder del proyecto

UNIVERSIDAD DE SEVILLA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 3670

Presupuesto del proyecto 226K€

Descripción del proyecto Celiac disease (CD) is a systemic autoimmune disorder triggered by gluten consumption in genetically predisposed individuals, affecting a substantial portion of the European population (1.4%). A significant number of CD cases remain undiagnosed (75%), leading to untreated disease and its associated symptoms. These range from immediate gastrointestinal and extra-intestinal distress to long-term complications such as osteoporosis, infertility, and cancer, among others, placing substantial strain on society and healthcare systems. As the primary treatment for CD remains a strict gluten-free diet, there is a pressing need for innovative approaches to alleviate the burden of inadvertent gluten exposure. This proposal aims to investigate the molecular mechanisms governing the transport of gluten immunogenic peptides (GIP) across the small intestine and to develop a chiral-based strategy for the design of enantiomeric peptides that can inhibit GIP toxicity and immunogenicity. Our objectives are: 1) To develop a focused library of enantiomeric peptide inhibitors of GIP that could be used as novel therapeutic agents for CD. 2) To elucidate the molecular mechanisms of GIP transport and immunogenicity across the small intestine using GIP enantiomers as probes. 3) To establish a liquid chromatography–mass spectrometry (LC-MS) assay for GIP quantitation in biological samples as a novel diagnostic tool for assessing gut permeability in CD patients. The successful accomplishment of these objectives will provide valuable insights into GIP activity and transport within intestinal epithelium and immune cells. Moreover, it offers the potential to identify novel peptide-based therapeutics against GIP, with the possibility of further commercialization. Lastly, the success of this proposal carries the critical importance of raising awareness about CD and pathologies associated with gluten consumption, addressing the alarming rate of undiagnosed cases within the European population.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores